Intelligent wound nursing system

Abstract

The invention relates to the technical field of medical instruments, in particular to an intelligent wound nursing system which comprises a dressing body, and the dressing body comprises a skin-friendly layer, a functional layer and a protective layer. A monitoring module, a control module, a medicine leading-in module, a flexible circuit layer and an alarm module are integrated in the functional layer. According to the method, the infection misdiagnosis rate is reduced through multi-sensor fusion monitoring and a preset infection risk threshold algorithm; according to the design, the micro-fluidic chip and the biological probe are integrated in the percolate component sensor, so that the infection detection rate is increased; a temperature-sensitive hydrogel micro-valve array and nanofiber membrane slow release technology is adopted, so that medicine waste or poor treatment effect is reduced; through a multi-sensor data fusion algorithm, the detection accuracy is improved; the layout of the micro-valve array and the annularly distributed independent medicine storage cavities is adopted, so that the release error is reduced; through the ultrathin flexible framework, the snakelike wiring circuit and flip chip packaging, circuit breakage is avoided, and the clinical failure rate is reduced.

Description

Technical Field

[0001] The present invention relates to the technical field of medical devices, and in particular to an intelligent wound care system. Background Art

[0002] In the field of wound care, traditional care methods and existing technologies have many limitations, which seriously affect wound healing and patient recovery experience: 1. Traditional dressings rely on experience and judgment, and the misdiagnosis rate is high: Traditional dressing changes mainly rely on medical staff to observe the color, smell and other subjective indicators of exudate with the naked eye to judge the infection situation. According to the 2023 literature data of "Trauma Nursing", the misdiagnosis rate of this method is as high as 35%, which can easily lead to delayed treatment of infection or unnecessary excessive intervention, increasing patient pain and medical costs.

[0003] 2. Commercial sensor dressings have single functions: Existing commercial sensor dressings, such as Smith & Nephew pH-sensitive dressings, can only monitor a single parameter (such as pH value) and cannot identify early infection biomarkers (such as bacterial metabolites and specific inflammatory factors). It is difficult to provide timely warnings in the early stages of infection, and the best time for treatment is missed.

[0004] 3. Passive drug release systems lack dynamic adjustment capabilities: Common passive drug release systems such as hydrogels have a fixed drug release rate and cannot dynamically adjust the dosage and type of drug according to the real-time status of the wound (such as the degree of infection and the healing stage), resulting in drug waste or poor treatment effect.

[0005] 4. Existing intelligent technologies have obvious technical bottlenecks: Monitoring disconnect: Although Chinese patent CN113876480A achieves joint monitoring of pH and temperature, it misses key indicators such as bacterial metabolites and cannot fully assess the wound microenvironment.

[0006] Rough drug delivery: U.S. Patent US20210000698A1 uses a mechanical pump for drug release, which has a dosage error of more than ±20%, making it difficult to meet the needs of precise treatment.

[0007] Structural rigidity: The smart Band-Aid developed by Zhejiang University suffers from excessive circuit rigidity, which can lead to circuit breakage when applied to wounds. The clinical failure rate is as high as 42%, seriously affecting system stability and reliability.

[0008] Therefore, those skilled in the art provide an intelligent wound care system to solve the problems raised in the above background technology. Summary of the Invention

[0009] In order to solve the above technical problems, the present invention provides an intelligent wound care system. The dressing comprises a dressing body, wherein the dressing body comprises a skin-friendly layer, a functional layer and a protective layer, wherein the skin-friendly layer, the functional layer and the protective layer are sequentially connected from bottom to top by a medical adhesive; The functional layer internally integrates a monitoring module, a control module, a drug introduction module, a flexible circuit layer, and an alarm module. The flexible circuit layer provides power and signal transmission channels for each module. The control module is connected to the monitoring module, the drug introduction module, and the alarm module through the flexible circuit layer, and an antenna interface is reserved for connection to an external Bluetooth module. The monitoring module includes a pH sensor, a temperature sensor and a transudate component sensor; The control module has a built-in preset infection risk threshold algorithm, which generates a drug release instruction when the monitoring data exceeds the threshold; The drug introduction module includes at least three independent drug storage chambers and a microvalve array.

[0010] Preferably, the pH sensor uses an ion-selective electrode to measure the pH of wound tissue fluid; The temperature sensor uses a thermistor to monitor the temperature of the wound; The exudate component sensor integrates a microfluidic chip and a biological probe to detect the concentrations of protein, glucose, interleukin and bacterial metabolites in the exudate. The exudate component sensor also includes a lactate oxidase-modified electrode to specifically detect the concentration of Staphylococcus aureus metabolites with a detection sensitivity of ≥0.5 μg / mL.

[0011] Preferably, the skin-friendly layer is in direct contact with the wound and is made of ultra-soft medical-grade spunlace non-woven fabric. The surface is treated with a nano-level hydrophilic coating, which has excellent liquid absorbency and breathability. It can quickly absorb wound exudate while keeping the wound surface dry, creating a good microenvironment for wound healing. The thickness of the skin-friendly layer is 0.1-0.3mm, ensuring soft fit and reducing friction and irritation to the wound. The protective layer is made of a transparent medical-grade polyurethane film with a thickness of 0.05-0.1mm. It has good waterproofness and flexibility, can effectively prevent the invasion of external pollutants, and does not affect the fit between the dressing body and the skin. Breathable micropores are set on the protective layer with a pore size of 0.1-1μm to ensure smooth gas exchange in the wound area.

[0012] Preferably, the sensors are distributed in a matrix manner in the middle area of ​​the functional layer, and the pH sensor and the temperature sensor are evenly arranged at intervals of 3-5 mm to form a basic monitoring array; the exudate component sensor is arranged at an edge position close to the convergence direction of the wound exudate, and the exudate component sensor is connected to the skin-friendly layer through a micro-guide groove to ensure that the exudate can flow into the sensor detection area in time; all sensors use flip-chip packaging technology, and electrical connection is achieved through the pads of the flexible circuit layer. The sensor package thickness does not exceed 0.2 mm to ensure that the overall structure is light and thin.

[0013] Preferably, the control module is located in the upper right corner of the functional layer, and adopts miniaturized system-level packaging technology to integrate the microcontroller, memory, power management chip, etc. into a package with a size of 5mm×5mm×1mm; The preset infection risk threshold of the control module is: When pH>7.4, temperature>38°C, and bacterial metabolite concentration>5μg / mL, the antibiotic release command is triggered; When the interleukin concentration is >100 pg / mL, the anti-inflammatory drug release instruction is triggered; When the glucose concentration is <3 mmol / L and the protein concentration decreases, the growth factor release command is triggered.

[0014] Preferably, the three independent drug storage chambers are respectively loaded with antibiotics, growth factors and anti-inflammatory drugs; The microvalve array responds to the control module's instruction to open the corresponding drug storage chamber; The microvalve array is made of thermosensitive hydrogel, which undergoes phase change and expansion after receiving instructions, opening the release channel of the drug storage cavity, with a release accuracy error of ≤±5%; The drug storage cavity is provided with a nanofiber membrane for slowing down the drug diffusion rate and achieving sustained release for 12-24 hours.

[0015] Preferably, the multiple drug storage cavities are distributed in an annular shape at the edge of the functional layer, 1-2 cm away from the edge of the dressing body, each drug storage cavity has a capacity of 0.1-0.5 ml, and is connected to the corresponding drug release unit through a micro-channel; The drug release unit is manufactured using micro-electromechanical system technology, installed below the drug storage cavity, and receives instructions from the control module through the flexible circuit layer to achieve precise drug release.

[0016] Preferably, the flexible circuit layer covers the entire functional layer, uses polyimide as the base material, and the circuit layer is made of nano silver paste through an inkjet printing process. The flexible circuit layer is provided with multi-layer wiring, which is used for signal transmission, power supply and grounding respectively. Each module is detachably connected to the flexible circuit layer through a gold finger connector, which is convenient for maintenance and replacement; The flexible circuit layer adopts a serpentine routing design, and the resistance change rate is less than 3% when the bending radius is ≤ 2mm. The flexible circuit layer includes an embedded Bluetooth module and a micro energy unit; The embedded Bluetooth module transmits monitoring data to an external terminal in real time; The micro energy unit provides power to the system.

[0017] Preferably, the alarm module includes a vibration motor and an LED light source. When the infection risk value exceeds a preset safety range, a tactile alarm is issued through the vibration motor; and a visual alarm is issued through the LED light source.

[0018] Preferably, the control module executes a multi-sensor data fusion algorithm, including: Compensate for pH sensor drift based on temperature data; The concentration values ​​of exudate components were corrected by impedance spectroscopy analysis; Output wound healing trend score (0-100 points).

[0019] Technical effects and advantages of the present invention: 1. To address the defect of traditional dressings that rely on visual observation, resulting in a high misdiagnosis rate of 35%, this system reduces the misdiagnosis rate of infection through multi-sensor fusion monitoring (pH sensor + temperature sensor + exudate composition sensor) and a preset infection risk threshold algorithm (such as the triple trigger mechanism of pH>7.4 + temperature>38℃ + bacterial metabolites>5μg / mL).

[0020] 2. To address the functional defect of commercial sensor dressings that can only monitor a single parameter, this design integrates a microfluidic chip and a biological probe into the exudate composition sensor to simultaneously detect four types of indicators: protein, glucose, interleukin, and bacterial metabolites. Combined with the directional drainage technology of the diversion groove, the infection detection rate is improved.

[0021] 3. To address the pain point that passive drug release systems cannot adjust drugs on demand, this system uses thermosensitive hydrogel microvalve arrays and nanofiber membrane sustained-release technology. Based on the intelligent decision-making instructions of the control module (such as interleukin >100pg / mL triggering the release of anti-inflammatory drugs), it dynamically adjusts the dosage and type of drug according to the real-time status of the wound (such as the degree of infection and the healing stage), thereby reducing drug waste or poor treatment effects.

[0022] 4. To address the defect of existing technologies in missing key biochemical indicators, a multi-sensor data fusion algorithm is used to improve detection accuracy and output a healing trend score of 0-100 points; To address the shortcoming of the ±20% high error in drug release from mechanical pumps, a microvalve array and an annularly distributed independent drug storage chamber layout are used to reduce the release error. To address the 42% clinical fracture rate of rigid circuits, an ultra-thin flexible architecture, serpentine routing circuits, and flip-chip packaging are used to avoid circuit fractures and reduce clinical failure rates. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 This is a block diagram of an intelligent wound care system provided by an embodiment of the present application; Figure 2 This is a structural diagram of a dressing body in an intelligent wound care system provided in an embodiment of the present application; Figure 3 This is a process of an intelligent wound care system provided by the embodiment of the present application Figure 1 ; Figure 4 This is a process of an intelligent wound care system provided by the embodiment of the present application Figure 2 ; In the picture: 100. Dressing body; 101. Skin-friendly layer; 102. Functional layer; 103. Protective layer; 200. Monitoring module; 201. pH sensor; 202. Temperature sensor; 203. Exudate component sensor; 300. Control module; 400. Drug introduction module; 401. Drug storage chamber; 402. Microvalve array; 403. Nanofiber membrane; 500. Flexible circuit layer; 501. Embedded Bluetooth module; 502. Micro energy unit; 600. Alarm module; 601. Vibration motor; 602. LED light source. DETAILED DESCRIPTION

[0024] The present invention will be described in further detail below with reference to the accompanying drawings and specific embodiments. The embodiments of the present invention are provided for purposes of illustration and description and are not intended to be exhaustive or to limit the invention to the disclosed forms. Many modifications and variations will be apparent to those skilled in the art. The embodiments are chosen and described to better illustrate the principles of the invention and its practical application, and to enable those skilled in the art to understand the invention and design various embodiments with various modifications suitable for specific applications. Example 1

[0025] See also Figures 1 to 4 In this embodiment, a smart wound care system is provided. The dressing comprises a dressing body 100, which includes a skin-friendly layer 101, a functional layer 102, and a protective layer 103. The skin-friendly layer 101, the functional layer 102, and the protective layer 103 are sequentially connected from bottom to top via a medical adhesive. The skin-friendly layer 101, which directly contacts the wound, is made of an ultra-soft medical-grade spunlace non-woven fabric with a nano-scale hydrophilic coating on the surface. The fabric has excellent liquid absorbency and breathability, can quickly absorb wound exudate, and keep the wound surface dry, creating a good microenvironment for wound healing. The skin-friendly layer 101 has a thickness of 0.1-0.3 mm, ensuring a soft fit and reducing friction and irritation to the wound. The protective layer 103 is made of a transparent medical-grade polyurethane film with a thickness of 0.05-0.1 mm. It has good waterproofness and flexibility, can effectively prevent the invasion of external pollutants, and does not affect the fit between the dressing body and the skin. Breathable micropores are provided on the protective layer with a pore size of 0.1-1 μm to ensure smooth gas exchange in the wound area.

[0026] The functional layer 102 internally integrates a monitoring module 200, a control module 300, a drug introduction module 400, a flexible circuit layer 500, and an alarm module 600. The flexible circuit layer 500 provides power and signal transmission channels for each module. The control module 300 establishes connections with the monitoring module 200, the drug introduction module 400, and the alarm module 600 through the flexible circuit layer 500, and an antenna interface is reserved for connection to an external Bluetooth module. The monitoring module 200 includes a pH sensor 201, a temperature sensor 202 and a transudate component sensor 203; The pH sensor 201 uses an ion-selective electrode to measure the pH of wound tissue fluid; The temperature sensor 202 uses a thermistor to monitor the wound temperature; The exudate component sensor 203 integrates a microfluidic chip and a biological probe to detect the concentrations of protein, glucose, interleukin, and bacterial metabolites in the exudate. The exudate component sensor 203 includes a lactate oxidase-modified electrode to specifically detect the concentration of Staphylococcus aureus metabolites with a detection sensitivity of ≥0.5 μg / mL. The sensors are arranged in a matrix pattern in the central region of the functional layer 102. The pH sensor 201 and temperature sensor 202 are evenly spaced 3-5 mm apart, forming a basic monitoring array. The exudate composition sensor 203 is positioned near the edge of the wound exudate convergence direction. It is connected to the skin-friendly layer 101 via micro-guiding grooves, ensuring that exudate flows into the sensor detection area in a timely manner. All sensors are packaged using flip-chip technology, with electrical connections achieved via pads on the flexible circuit layer. The sensor package thickness does not exceed 0.2 mm, ensuring a thin and lightweight overall structure.

[0027] The control module 300 has a built-in preset infection risk threshold algorithm, which generates a drug release instruction when the monitoring data exceeds the threshold; The control module 300 is located in the upper right corner of the functional layer 102 and uses miniaturized system-level packaging technology to integrate the microcontroller, memory, power management chip, etc. into a package with a size of 5mm×5mm×1mm; The preset infection risk threshold of the control module 300 is: When pH>7.4, temperature>38°C, and bacterial metabolite concentration>5μg / mL, the antibiotic release command is triggered; When the interleukin concentration is >100 pg / mL, the anti-inflammatory drug release instruction is triggered; When the glucose concentration is <3 mmol / L and the protein concentration decreases, the growth factor release command is triggered; The control module 300 executes a multi-sensor data fusion algorithm, including: Compensate for pH sensor drift based on temperature data; The concentration values ​​of exudate components were corrected by impedance spectroscopy analysis; Output wound healing trend score 0-100 points.

[0028] The drug introduction module 400 includes at least three independent drug storage chambers 401 and a microvalve array 402; The three independent drug storage chambers 401 are respectively loaded with antibiotics, growth factors and anti-inflammatory drugs; The microvalve array 402 opens the corresponding drug storage chamber 401 in response to the instruction of the control module 300; The microvalve array 402 is made of thermosensitive hydrogel, which undergoes phase change and expansion after receiving a command, opening the release channel of the drug storage chamber 401, with a release accuracy error of ≤±5%; The drug storage chamber 401 is provided with a nanofiber membrane 403 for slowing down the drug diffusion rate and achieving sustained release for 12-24 hours; The multiple drug storage cavities 401 are distributed in an annular shape at the edge of the functional layer 102, 1-2 cm away from the edge of the dressing body. Each drug storage cavity 401 has a capacity of 0.1-0.5 ml and is connected to the corresponding drug release unit through a micro-channel. The drug release unit is manufactured using micro-electromechanical system (MEMS) technology, is installed below the drug storage chamber 401, and receives instructions from the control module 300 through the flexible circuit layer 500 to achieve precise drug release.

[0029] The flexible circuit layer 500 covers the entire functional layer 102 and uses polyimide PI as the base material. The circuit layer is made of nano-silver paste through an inkjet printing process. The flexible circuit layer is provided with multi-layer wiring for signal transmission, power supply and grounding respectively. Each module is detachably connected to the flexible circuit layer through a gold finger connector, which is convenient for maintenance and replacement. The flexible circuit layer 500 adopts a serpentine routing design, and the resistance change rate is less than 3% when the bending radius is ≤ 2 mm. The flexible circuit layer 500 includes an embedded Bluetooth module 501 and a micro energy unit 502; The embedded Bluetooth module 501 transmits monitoring data to an external terminal in real time; The micro energy unit 502 provides power for the system.

[0030] The alarm module 600 includes a vibration motor 601 and an LED light source 602. When the infection risk value exceeds a preset safety range, a tactile alarm is issued through the vibration motor 601; and a visual alarm is issued through the LED light source 602. Example 2

[0031] 1. Layered structure of dressing body 100 Skin-friendly layer 101: The fabric is made of 0.15mm thick medical viscose spunlace non-woven fabric (weight 32g / m²), sprayed with a nano-SiO2 hydrophilic coating (contact angle 8°), and equipped with radial micro-channels (200μm wide and 150μm deep). The liquid absorption rate is 0.15ml / cm²·s (test standard ISO9073-6). Functional layer 102: Total thickness 0.5mm, made of medical grade silicone base (Shore hardness 00-30) to support the following modules: Monitoring module 200: pH sensor 201 (PVC membrane ion selective electrode, detection range 5.0-9.0, accuracy ±0.1) Temperature sensor 202 (NTC thermistor, range 25-45°C, accuracy ±0.2°C) Matrix layout: 5×5 array, 4mm pitch (covering ≥80% of the wound area) Exudate composition sensor 203: Integrated PDMS microfluidic chip (channel width 100 μm) with lactate oxidase / glucose oxidase dual-modified electrodes (sensitivity to S. aureus metabolites 0.48 μg / mL) Control module 300: SiP package (5mm×5mm×1mm), built-in ARM Cortex-M4 processor, storage infection threshold algorithm Drug introduction module 400: At least 3 polycarbonate storage chambers 401 (circular distribution, 1.5 cm from the edge, volume 0.3 ml) Loaded drugs: Mupirocin (antibiotic), bFGF (growth factor), ketoprofen (anti-inflammatory drug) Microvalve array 402: Thermosensitive PNIPAM hydrogel (phase transition temperature 32±0.5°C), expansion rate 350% Nanofiber membrane 403: PLGA electrospun membrane (pore size 50-100nm), sustained release time 18±2h Protective layer 103: 0.08mm transparent polyurethane film, CO2 laser punched to form micropores with a pore size of 0.5±0.1μm (density 200 holes / mm²), and a moisture permeability of 2300g / m²·day (test standard ASTM E96).

[0032] 2. Flexible circuit layer 500 Substrate: 25μm polyimide (PI) film Circuit: Inkjet printed nano silver paste (silver content 85%, square resistance 0.07Ω / sq), serpentine routing (line width / spacing = 80μm / 40μm) Connection: 1.27mm pitch gold finger connector (gold plating thickness 2.5μm, insertion and removal force 0.6N) Energy unit 502: 3.7V 12mAh solid-state lithium thin film battery (cycle life > 500 times) Bluetooth module 501: BLE5.2 protocol, transmission distance > 10m 3. Alarm module 600 Vibration motor 601: 6mm diameter, 1.5G amplitude (continuous vibration for 3 seconds when triggered) LED light source 602: RGB three-color light, red light flashes when infection alarm occurs (frequency 2Hz). Example 3

[0033] Drug release accuracy verification Test method: The wound environment (37°C, pH 7.6) was simulated, and the antibiotic release command was triggered 10 times. The amount of mupirocin released was detected by HPLC.

[0034] result Release times Theoretical dose (μg) Actual dose (μg) error 1 150 156 +4% 5 150 143 -4.7% Average error ≤±4.8% (meets the requirement of ≤±5%) Example 4: Flexible Circuit Reliability Test condition: According to ASTM F2878, the dressing was attached to a cylinder with a radius of 2 mm and bent at a frequency of 1 Hz.

[0035] Number of cycles Resistance change rate Signal packet loss rate 0 0% 0% 500 1.8% 0.1% 1000 2.9% 0.3% Resistance change <3% when bending radius ≤ 2mm In the scheme, unless otherwise clearly stipulated and limited, the terms "install", "set", "connect", "fix", "screw" and the like should be understood in a broad sense. For example, it can be a fixed connection, a detachable connection, or an integrated connection; it can be a mechanical connection or an electrical connection; it can be a direct connection or an indirect connection through an intermediate medium; it can be the internal connection of two elements or the interaction relationship between two elements. Unless otherwise clearly defined, ordinary technicians in this field can understand the specific meanings of the above terms in this scheme according to the specific circumstances.

[0036] Obviously, the embodiments described are only some of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field and related fields without making creative efforts should fall within the scope of protection of the present invention. Structures, devices, and operating methods not specifically described and explained in the present invention shall be implemented in accordance with conventional means in the field unless otherwise specified or limited.

Claims

1. An intelligent wound care system, characterized in that: The dressing comprises a dressing body (100), wherein the dressing body (100) comprises a skin-friendly layer (101), a functional layer (102), and a protective layer (103), wherein the skin-friendly layer (101), the functional layer (102), and the protective layer (103) are connected sequentially from bottom to top via a medical adhesive; The functional layer internally integrates a monitoring module (200), a control module (300), a drug introduction module (400), a flexible circuit layer (500), and an alarm module (600), wherein the flexible circuit layer (500) provides power and signal transmission channels for each module; the control module (300) establishes a connection with the monitoring module (200), the drug introduction module (400), and the alarm module (600) via the flexible circuit layer (500), and at the same time reserves an antenna interface for connection with an external Bluetooth module; The monitoring module (200) comprises a pH sensor (201), a temperature sensor (202), and an exudate component sensor (203); The control module (300) has a built-in preset infection risk threshold algorithm, which generates a drug release instruction when the monitoring data exceeds the threshold; The drug introduction module (400) comprises at least three independent drug storage chambers (401) and a microvalve array (402).

2. The intelligent wound care system according to claim 1, characterized in that: The pH sensor (201) uses an ion-selective electrode to measure the pH of wound tissue fluid; The temperature sensor (202) uses a thermistor to monitor the temperature of the wound; The exudate component sensor (203) integrates a microfluidic chip and a biological probe to detect the concentrations of protein, glucose, interleukin and bacterial metabolites in the exudate, and the exudate component sensor (203) includes a lactate oxidase-modified electrode to specifically detect the concentration of Staphylococcus aureus metabolites, with a detection sensitivity of ≥0.5 μg / mL.

3. The intelligent wound care system according to claim 1, characterized in that: The skin-friendly layer (101) is in direct contact with the wound and is made of ultra-soft medical-grade spunlace non-woven fabric, the surface of which is treated with a nano-scale hydrophilic coating. The thickness of the skin-friendly layer (101) is 0.1-0.3 mm; The protective layer (103) is made of a transparent medical-grade polyurethane film with a thickness of 0.05-0.1 mm. Breathable micropores are provided on the protective layer with a pore size of 0.1-1 μm.

4. The intelligent wound care system according to claim 1, characterized in that: The sensors are distributed in a matrix-like manner in the middle area of ​​the functional layer (102), and the pH sensor (201) and the temperature sensor (202) are evenly arranged at intervals of 3-5 mm to form a basic monitoring array; the exudate component sensor (203) is arranged at an edge position close to the direction of convergence of wound exudate, and the exudate component sensor (203) is connected to the skin-friendly layer (101) through a micro-guiding groove. All sensors adopt flip-chip packaging technology and realize electrical connection through the pads of the flexible circuit layer. The sensor packaging thickness does not exceed 0.2 mm.

5. The intelligent wound care system according to claim 1, characterized in that: The control module (300) is located at the upper right corner of the functional layer (102) and uses miniaturized system-level packaging technology to integrate a microcontroller, memory, power management chip, etc. into a package with a size of 5mm×5mm×1mm; The preset infection risk threshold of the control module (300) is: When pH>7.4, temperature>38°C, and bacterial metabolite concentration>5μg / mL, the antibiotic release command is triggered; When the interleukin concentration is >100 pg / mL, the anti-inflammatory drug release instruction is triggered; When the glucose concentration is <3 mmol / L and the protein concentration decreases, the growth factor release command is triggered.

6. The intelligent wound care system according to claim 1, characterized in that: The three independent drug storage chambers (401) are respectively loaded with antibiotics, growth factors and anti-inflammatory drugs; The microvalve array (402) opens the corresponding drug storage chamber (401) in response to an instruction from the control module (300); The microvalve array (402) is composed of a thermosensitive hydrogel, which undergoes phase change and expansion after receiving a command, thereby opening the release channel of the drug storage chamber (401), with a release accuracy error of ≤±5%; The drug storage cavity (401) is provided with a nanofiber membrane (403) for slowing down the drug diffusion rate and achieving sustained release for 12-24 hours.

7. The intelligent wound care system according to claim 6, characterized in that: The plurality of drug storage cavities (401) are distributed in an annular shape at the edge of the functional layer (102), 1-2 cm away from the edge of the dressing body, each drug storage cavity (401) has a capacity of 0.1-0.5 ml and is connected to a corresponding drug release unit via a micro-channel; The drug release unit is manufactured using micro-electromechanical system (MEMS) technology, is installed below the drug storage cavity (401), and receives instructions from the control module (300) through the flexible circuit layer (500) to achieve precise drug release.

8. The intelligent wound care system according to claim 1, characterized in that: The flexible circuit layer (500) covers the entire functional layer (102), uses polyimide (PI) as a base material, and the circuit layer is made of nano silver paste through an inkjet printing process. The flexible circuit layer is provided with multi-layer wiring, which is used for signal transmission, power supply and grounding respectively. Each module is detachably connected to the flexible circuit layer through a gold finger connector; The flexible circuit layer (500) adopts a serpentine routing design, and the resistance change rate is less than 3% when the bending radius is ≤2 mm. The flexible circuit layer (500) includes an embedded Bluetooth module (501) and a micro energy unit (502); The embedded Bluetooth module (501) transmits monitoring data to an external terminal in real time; The micro energy unit (502) provides power for the system.

9. The intelligent wound care system according to claim 1, characterized in that: The alarm module (600) comprises a vibration motor (601) and an LED light source (602). When the infection risk value exceeds a preset safety range, a tactile alarm is issued through the vibration motor (601); and a visual alarm is issued through the LED light source (602).

10. The intelligent wound care system according to claim 1, characterized in that: The control module (300) executes a multi-sensor data fusion algorithm, including: Compensate for pH sensor drift based on temperature data; The concentration values ​​of exudate components were corrected by impedance spectroscopy analysis; Output wound healing trend score (0-100 points).

Images